Credit Suisse Reiterates Underperform on Cochlear (COH)
Cochlear (ASX: COH)‘s stock had its “underperform” rating restated by equities researchers at Credit Suisse in a report issued on Wednesday. They currently have a $80.00 (76 AUD) target price on the stock.
Cochlear remained flat at A$80.000 during trading on Wednesday. Cochlear has a 52-week low of A$51.310 and a 52-week high of A$71.790. The stock’s 50-day moving average is currently A$68.1. The company has a market cap of A$4.549 billion and a price-to-earnings ratio of 80.16.
COH has been the subject of a number of other recent research reports. Analysts at Macquarie reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Friday, November 23rd. They now have a $71.35 price target on the stock. Separately, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Monday, November 12th. They now have a $67.71 price target on the stock. Finally, analysts at Nomura reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Tuesday, October 30th. They now have a $70.31 price target on the stock.
Cochlear Limited (Cochlear) is an Australia-based company, which operates in the implantable hearing device industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.